-
Something wrong with this record ?
Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates
O. Lidický, O. Janoušková, J. Strohalm, M. Alam, P. Klener, T. Etrych,
Language English Country Switzerland
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 1997
Free Medical Journals
from 1997
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 1997-01-01
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 2009-03-01
Health & Medicine (ProQuest)
from 1997-01-01
- MeSH
- Apoptosis drug effects MeSH
- Doxorubicin chemistry pharmacology MeSH
- Drug Delivery Systems MeSH
- Humans MeSH
- Lymphoma drug therapy mortality pathology MeSH
- Disease Models, Animal MeSH
- Mice MeSH
- Cell Line, Tumor MeSH
- Polymers * chemistry MeSH
- Prodrugs * chemistry pharmacology MeSH
- Antineoplastic Agents chemistry pharmacology MeSH
- Rituximab chemistry pharmacology MeSH
- Drug Liberation MeSH
- Cell Survival drug effects MeSH
- Xenograft Model Antitumor Assays MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Here we describe the synthesis and biological properties of two types of star-shaped polymer-doxorubicin conjugates: non-targeted conjugate prepared as long-circulating high-molecular-weight (HMW) polymer prodrugs with a dendrimer core and a targeted conjugate with the anti-CD20 monoclonal antibody (mAb) rituximab (RTX). The copolymers were linked to the dendrimer core or to the reduced mAb via one-point attachment forming a star-shaped structure with a central antibody or dendrimer surrounded by hydrophilic polymer chains. The anticancer drug doxorubicin (DOX) was attached to the N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymer chain in star polymer systems via a pH-labile hydrazone linkage. Such polymer-DOX conjugates were fairly stable in aqueous solutions at pH 7.4, and the drug was readily released in mildly acidic environments at pH 5-5.5 by hydrolysis of the hydrazone bonds. The cytotoxicity of the polymer conjugates was tested on several CD20-positive or negative human cell lines. Similar levels of in vitro cytotoxicity were observed for all tested polymer conjugates regardless of type or structure. In vivo experiments using primary cell-based murine xenograft models of human diffuse large B-cell lymphoma confirmed the superior anti-lymphoma efficacy of the polymer-bound DOX conjugate when compared with the original drug. Targeting with RTX did not further enhance the anti-lymphoma efficacy relative to the non-targeted star polymer conjugate. Two mechanisms could play roles in these findings: changes in the binding ability to the CD-20 receptor and a significant loss of the immunological properties of RTX in the polymer conjugates.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16027975
- 003
- CZ-PrNML
- 005
- 20161027102053.0
- 007
- ta
- 008
- 161005s2015 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules201119664 $2 doi
- 024 7_
- $a 10.3390/molecules201119664 $2 doi
- 035 __
- $a (PubMed)26556320
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Lidický, Ondřej $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic. lidicky@imc.cas.cz.
- 245 10
- $a Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates / $c O. Lidický, O. Janoušková, J. Strohalm, M. Alam, P. Klener, T. Etrych,
- 520 9_
- $a Here we describe the synthesis and biological properties of two types of star-shaped polymer-doxorubicin conjugates: non-targeted conjugate prepared as long-circulating high-molecular-weight (HMW) polymer prodrugs with a dendrimer core and a targeted conjugate with the anti-CD20 monoclonal antibody (mAb) rituximab (RTX). The copolymers were linked to the dendrimer core or to the reduced mAb via one-point attachment forming a star-shaped structure with a central antibody or dendrimer surrounded by hydrophilic polymer chains. The anticancer drug doxorubicin (DOX) was attached to the N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymer chain in star polymer systems via a pH-labile hydrazone linkage. Such polymer-DOX conjugates were fairly stable in aqueous solutions at pH 7.4, and the drug was readily released in mildly acidic environments at pH 5-5.5 by hydrolysis of the hydrazone bonds. The cytotoxicity of the polymer conjugates was tested on several CD20-positive or negative human cell lines. Similar levels of in vitro cytotoxicity were observed for all tested polymer conjugates regardless of type or structure. In vivo experiments using primary cell-based murine xenograft models of human diffuse large B-cell lymphoma confirmed the superior anti-lymphoma efficacy of the polymer-bound DOX conjugate when compared with the original drug. Targeting with RTX did not further enhance the anti-lymphoma efficacy relative to the non-targeted star polymer conjugate. Two mechanisms could play roles in these findings: changes in the binding ability to the CD-20 receptor and a significant loss of the immunological properties of RTX in the polymer conjugates.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a doxorubicin $x chemie $x farmakologie $7 D004317
- 650 _2
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a uvolňování léčiv $7 D065546
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfom $x farmakoterapie $x mortalita $x patologie $7 D008223
- 650 _2
- $a myši $7 D051379
- 650 12
- $a polymery $x chemie $7 D011108
- 650 12
- $a prekurzory léčiv $x chemie $x farmakologie $7 D011355
- 650 _2
- $a rituximab $x chemie $x farmakologie $7 D000069283
- 650 _2
- $a xenogenní modely - testy protinádorové aktivity $7 D023041
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Janoušková, Olga $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic. janouskova@imc.cas.cz.
- 700 1_
- $a Strohalm, Jiří $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic. strohalm@imc.cas.cz.
- 700 1_
- $a Alam, Mahmudul $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, U Nemocnice 5, 128 53 Prague 2, Czech Republic. mahmuddso2004@gmail.com. $7 gn_A_00003252
- 700 1_
- $a Klener, Pavel $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, U Nemocnice 5, 128 53 Prague 2, Czech Republic. pavel.klener@gmail.com. Department of Hematology, Charles University General Hospital in Prague, U Nemocnice 2, 128 08 Prague 2, Czech Republic. pavel.klener@gmail.com.
- 700 1_
- $a Etrych, Tomáš $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Heyrovský Sq. 2, 162 06 Prague 6, Czech Republic. etrych@imc.cas.cz.
- 773 0_
- $w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 20, č. 11 (2015), s. 19849-64
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26556320 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161027102510 $b ABA008
- 999 __
- $a ok $b bmc $g 1166289 $s 952605
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 20 $c 11 $d 19849-64 $e 20151104 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- LZP __
- $a Pubmed-20161005
